Bacterial vaginosis: Review of treatment options and potential clinical indications for therapy

被引:76
作者
Joesoef, MR
Schmid, GP
Hillier, SL
机构
[1] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA
[2] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA
关键词
D O I
10.1086/514725
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We reviewed data on the treatment of bacterial vaginosis published from 1993 through 1996. For nonpregnant women, we recommend use of metronidazole (500 mg orally twice daily for 7 days), clindamycin vaginal cream (2%, once daily for 7 days), or metronidazole vaginal gel (0.75%, twice daily for 5 days) as the preferred treatment for bacterial vaginosis. For pregnant high-risk women (women with a prior preterm birth), the objective of the treatment is to prevent adverse outcomes of pregnancy, in addition to relief of symptoms. Thus, systemic therapy for possible subclinical upper tract infection as well as medication that has been studied in pregnant women are preferable. Therefore, we recommend metronidazole (250 mg orally three times a day for 7 days). For pregnant low-risk women (women without a prior preterm birth) with symptomatic diseases, the main objective of the treatment is to relieve symptoms. We recommend metronidazole (250 mg orally three times a day for 7 days). Data do not support routine treatment of male sex partners.
引用
收藏
页码:S57 / S65
页数:9
相关论文
共 60 条
  • [1] NONSPECIFIC VAGINITIS - DIAGNOSTIC-CRITERIA AND MICROBIAL AND EPIDEMIOLOGIC ASSOCIATIONS
    AMSEL, R
    TOTTEN, PA
    SPIEGEL, CA
    CHEN, KCS
    ESCHENBACH, D
    HOLMES, KK
    [J]. AMERICAN JOURNAL OF MEDICINE, 1983, 74 (01) : 14 - 22
  • [2] CLINDAMYCIN VAGINAL CREAM VERSUS ORAL METRONIDAZOLE IN THE TREATMENT OF BACTERIAL VAGINOSIS - A PROSPECTIVE DOUBLE-BLIND CLINICAL-TRIAL
    ANDRES, FJ
    PARKER, R
    HOSEIN, I
    BENRUBI, GI
    [J]. SOUTHERN MEDICAL JOURNAL, 1992, 85 (11) : 1077 - 1080
  • [3] AVONTS D, 1990, SEX TRANSM DIS, V17, P23
  • [4] A FOLLOW-UP-STUDY OF METHODS OF CONTRACEPTION, SEXUAL-ACTIVITY, AND RATES OF TRICHOMONIASIS, CANDIDIASIS, AND BACTERIAL VAGINOSIS
    BARBONE, F
    AUSTIN, H
    LOUV, WC
    ALEXANDER, WJ
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (02) : 510 - 514
  • [5] ABSORPTION OF CLINDAMYCIN AFTER INTRAVAGINAL APPLICATION OF CLINDAMYCIN PHOSPHATE 2-PERCENT CREAM
    BORIN, MT
    POWLEY, GW
    TACKWELL, KR
    BATTS, DH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (06) : 833 - 841
  • [6] SIALIDASES (NEURAMINIDASES) IN BACTERIAL VAGINOSIS AND BACTERIAL VAGINOSIS-ASSOCIATED MICROFLORA
    BRISELDEN, AM
    MONCLA, BJ
    STEVENS, CE
    HILLIER, SL
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (03) : 663 - 666
  • [7] SAFETY OF METRONIDAZOLE IN PREGNANCY - A METAANALYSIS
    BURTIN, P
    TADDIO, A
    ARIBURNU, O
    EINARSON, TR
    KOREN, G
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (02) : 525 - 529
  • [8] CANTU JM, 1982, BIRTH DEFECTS-ORIG, V18, P85
  • [9] Centers for Disease Control and Prevention, 1993, Mort Morb Week Rep, V42, P27
  • [10] PHARMACOKINETICS OF INTRAVAGINAL METRONIDAZOLE GEL
    CUNNINGHAM, FE
    KRAUS, DM
    BRUBAKER, L
    FISCHER, JH
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (11) : 1060 - 1065